Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
— Acinetobacter Infections Pose Growing Concern in Hospitals, and in Military and Natural Disaster Trauma Centers — — Company Engages Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive to Provide Expertise on Advancing Infectious Disease Pipeline — ANN ARBOR, Mich., Sept. 18, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and […]